Gitnux/Report 2026

Neurotech Industry Statistics

Neurotech Industry’s statistics page tracks where the money, evidence, and regulators are moving fastest, from $34.8 billion in global brain stimulation market forecast for 2032 and $7.9 billion for 2032 medical BCI to a 2020–2023 FDA 510(k) count of 46 neurostimulation device submissions. You will also see what it costs and what it delivers, including 31% higher symptom improvement in real world evidence for closed loop neuromodulation and serious adverse events reported at 0.4% across pooled studies.
255Statistics
74Sources
12Sections
1Visuals
43mRead
November 10, 2026Updated
Neurotech Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Edited by Megan Gallagher·Fact-checked by Claire Beaumont
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The neurotech industry at a glance

The global neurotechnology market was estimated at $17.73 billion in 2025 and is projected to reach $32.93 billion by 2034, as neuromodulation, neuroprosthetics and brain-computer interfaces expand beyond specialist care.

$17.73B[20]
Global market size, 2025
7.0%[20]
Forecast CAGR, 2026–2034
$149.2M[21]
Neuronetics revenue, 2025
$100.0M[21]
NeuroPace revenue, 2025
Market size
Fortune Business Insights estimated the global neurotechnology market at $17.73 billion in 2025 and $19.19 billion in 2026. The estimate covers neuroprosthetics, neuromodulation, neurorehabilitation and related products and services.[20]
Forecast & CAGR
The market is forecast to reach $32.93 billion by 2034, implying a 7.0% compound annual growth rate from 2026 to 2034. A separate Mordor Intelligence estimate puts the market at $15.77 billion in 2025 and forecasts $33.05 billion by 2031 at a 13.12% CAGR, reflecting differing market definitions.[20][62]
Market share & regions
Fortune Business Insights identifies North America as a leading regional market, supported by healthcare infrastructure, research activity and adoption of neurological devices. The report also segments the market across Europe, Asia-Pacific, Latin America and the Middle East and Africa, but does not publish a directly comparable regional percentage in the accessible summary.[20]
Segmentation
The market is segmented by product into neuroprosthetics, neuromodulation, neurorehabilitation and other technologies; by application into Parkinson’s disease, epilepsy, Alzheimer’s disease and other conditions; and by end user into hospitals, specialty clinics, homecare settings and other facilities.[20]
Key players & concentration
Public-company filings show substantial scale differences among specialist suppliers: Neuronetics reported $149.2 million in 2025 revenue, NeuroPace reported $100.0 million and ClearPoint Neuro reported $37.0 million. These figures are company revenues rather than market shares, so they do not establish overall industry concentration.[21]
Pricing
Pricing varies by modality and reimbursement pathway. Neurotech Reports cited approximately $5,000 in durable-medical-equipment reimbursement for the Noctrix device, illustrating the difference between reimbursed neuromodulation equipment and cash-pay or investigational products.[63]
Trends, drivers & challenges
Growth is being driven by adaptive and closed-loop neuromodulation, home-based treatment and improved neurodiagnostics. Regulatory and clinical hurdles remain material: the FDA’s Flow FL-100 approval noted moderate uncertainty about benefit because of unblinding, the lack of a prespecified clinically significant score change and conflicting literature.[42][58]
Consumer behavior & competition
Commercial demand is increasingly shifting toward outpatient, home and digitally supported care. Neuronetics reported 261,591 unique patients treated and 9,446,469 treatments administered through September 30, 2026, while competition spans clinic-based systems, home neuromodulation, implanted stimulators and emerging brain-computer interfaces.[21][18]
M&A
M&A is concentrating around complementary neurovascular, neuromodulation and diagnostic capabilities. Medtronic disclosed that it completed the acquisition of Scientia Vascular on June 12, 2026, adding temporary peripheral-nerve-stimulation technology to its Neuroscience portfolio; NeuroVision Imaging announced its acquisition of Durin Life Sciences in May 2026.[21][64]
Regulation
U.S. regulation remains device-specific and risk-based. In 2025, the FDA granted Flow FL-100 premarket approval as a prescription cranial electrotherapy stimulator for adults with moderate-to-severe major depressive disorder, while the Delphi-MD System received De Novo classification as a Class II non-invasive evoked-response brain stimulator.[42]
Latest news
Recent developments include the FDA’s approval of Medtronic’s BrainSense adaptive deep-brain-stimulation system for Parkinson’s disease in February 2025, FDA approval of Flow FL-100 in December 2025, and Wave Neuroscience’s 510(k) clearance for the MeRT System in June 2026.[65][42]
report visual · Comparison

Global brain-computer interface market share by BCI type

Non-invasive holds the largest share at 77%.

Non-invasive77%
Invasive15.4%
Partially invasive7.6%
source-verifiedbccresearch.com

02 Ranking

Top 10 Companies in the Neurotech Industry

The leading companies in the neurotech industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 9, 2026 · Next review December 9, 2026

Verdict

Boston Scientific leads Gitnux's 2026 neurotech ranking with an Overall score of 9.5, with its Neuromodulation business generating $1.199 billion in 2025 sales. Medtronic is the runner-up at 9.1, driven by Neuroscience Portfolio revenue of $10.287 billion in FY26.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in neuromodulation devices

    Boston Scientific

    US

    Ranked #1 · 9.5 · Neuromodulation devices

    Why we picked it: Its neuromodulation segment reports $1.199 billion in 2025 sales and an 18% operating margin.

    See in ranking ↓Visit bostonscientific.com ↗

  2. Leader in point-of-care EEG

    Ceribell

    US

    Ranked #3 · 9.0 · Point-of-care EEG

    Why we picked it: Its point-of-care rapid EEG system is deployed in more than 600 U.S. hospitals.

    See in ranking ↓Visit ceribell.com ↗

  3. Leader in intracortical BCI systems

    Blackrock Neurotech

    US

    Ranked #4 · 8.7 · Intracortical BCI systems

    Why we picked it: Its intracortical Utah Array has been used in human BCI implants since 2004.

    See in ranking ↓Visit blackrockneurotech.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the neurotech industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Boston Scientific

Neuromodulation devices · US

9.5
2

Medtronic

Neuromodulation devices · IE

9.1
3

Ceribell

Point-of-care EEG · US

9.0
4

Blackrock Neurotech

Intracortical BCI systems · US

8.7
5

LivaNova

Neuromodulation devices · GB

8.7
6

Neuralink

Implantable brain-computer interfaces · US

8.5
7

Precision Neuroscience

Cortical surface neural interfaces · US

8.3
8

Cochlear

Cochlear implants and implantable hearing · AU

8.2
9

Paradromics

High-bandwidth implantable BCIs · US

8.2
10

g.tec medical engineering

EEG and brain-computer-interface systems · AT

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 9, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, February 13). Top 10 companies in the neurotech industry. In Neurotech Industry Statistics. Gitnux. https://gitnux.org/neurotech-industry-statistics/#top-companies

04 Statistics

Technology & Innovation

Digital transformation varies sharply across medtech: in 2021, 29% met or exceeded targets with sustainable change.

Digital Transformation in the medical devices sector (sector benchmark)

  • Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[1]
  • Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[1]
  • Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[2]
  • Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[2]
  • Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[1]
  • Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[3]

Technology Adoption in the medical devices sector (sector benchmark)

  • Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[4]
  • Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[4]
  • Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[5]
  • Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[5]
  • Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[4]
  • Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[4]

Cloud Computing in the medical devices sector (sector benchmark)

  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[6]
  • Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[5]
  • Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[5]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[6]

Big Data in the medical devices sector (sector benchmark)

  • 59% of medtech strategy and finance leaders prioritized advanced analytics for revenue management, compared with 57% for GenAI and 32% for AI/ML, in 2025.[7]
  • Across medtech companies surveyed by Model N, nearly 70% already used or planned to use data and analytics in 2023.[7]
  • 15.3% of SMEs in Europe’s healthcare industrial ecosystem had adopted big data and related data analytics, according to the 2023 EMI survey.[4]
  • Across medtech and biopharma companies surveyed in 2018, 67% of medtech firms invested in data analytics for reporting.[8]
  • Across healthcare industrial-ecosystem SMEs in Europe, 15.3% had adopted big data and related data analytics in 2023.[4]
  • 49% of medtech companies reported struggling with untimely data in Model N’s 2025 survey of industry leaders.[7]

IoT in the medical devices sector (sector benchmark)

  • Among European healthcare industrial-ecosystem SMEs already using IoT, 21.4% used predictive maintenance for production assets in 2023.[4]
  • Across healthcare industrial-ecosystem SMEs in Europe, 20.4% already used Internet of Things technologies in 2023.[4]
  • Among healthcare and medical-device IoT respondents, 84% planned to increase their connected-device estate in 2023.[9]
  • Among healthcare and medical-device IoT respondents, 31% planned to double the number of connected devices deployed in 2023.[9]
  • Among healthcare and medical-device IoT respondents, 9% had deployed between 10,001 and 100,000 connected devices in 2023.[10]
  • Among European healthcare industrial-ecosystem SMEs already using IoT, 22.3% used energy-saving devices such as smart lighting, HVAC or elevators in 2023.[4]

Innovation in the neurotech industry

  • 6,661 neurotechnology patents were granted to inventors in the United States in 2022.[11]
  • 9,350 neurotechnology patents were granted globally in 2022, up from 3,491 in 2013.[11]

05 Statistics

Data & Analytics

Analytics and data governance show up as execution constraints: 51% of medical-device companies still managed postmarket-surveillance manually or partially manually in 2025.

Data analytics in the neurotech industry

  • 2009 was the release year of Neurotechnology’s VeriLook Surveillance real-time face-identification product, later rebranded SentiVeillance.[12]
  • 2025 was the release year of Neurotechnology’s AI SDK for building secure natural-language-processing solutions.[12]
  • 2019 was the release year of Neurotechnology’s StockGeist.ai platform for natural-language processing and stock-market analysis.[12]
  • 2012 was the year Neurotechnology launched SkyBiometry, a subsidiary providing AI-factory and infrastructure-engineering services for production AI systems.[12]
  • 1.43 billion U.S. dollars was the estimated global brain-computer-interface market size in 2021, according to an IEC business-plan assessment of the sector.[13]
  • 2.62 billion U.S. dollars was the estimated global brain-machine-interface market size in 2024 in the Digital Economy Trends 2026 report.[14]

Data Quality in the medical devices sector (sector benchmark)

  • 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[15]
  • 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[16]
  • 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[5]
  • 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[16]
  • 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[17]

Data Governance in the medical devices sector (sector benchmark)

  • 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[17]
  • More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[17]
  • More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[17]
  • 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[17]

KPIs in the neurotech industry

  • 8.7% of patients in a 2010–2021 U.S. deep-brain-stimulation review were readmitted within 90 days after treatment.[18]
  • 14.3% of patients in a 2010–2021 U.S. deep-brain-stimulation review had an emergency-department visit within 90 days after treatment.[18]
  • 1.92% of patients in Medtronic’s 2024 deep-brain-stimulation registry were implanted for epilepsy.[19]
  • 518 product-performance events were reported in Medtronic’s deep-brain-stimulation registry between July 2009 and October 31, 2023.[19]
  • 18.1% was the three-year reoperation rate for non-implantable-pulse-generator-related reasons in a 2010–2021 U.S. deep-brain-stimulation review.[18]
  • 22.1% of all reported events in Medtronic’s 2023 deep-brain-stimulation registry were product-performance events.[19]

06 Statistics

Strategy & Growth

Specialist suppliers show revenue scale differences and measurable clinic adoption effects; Neuronetics reported $149.2M revenue in 2025.

Growth in the neurotech industry

  • 7.0% was the forecast compound annual growth rate for the global neurotechnology market from 2026 to 2034 in Fortune Business Insights’ forecast.[20]
  • $1.039 million in BCI revenue was reported by Visionsys for 2025, compared with no BCI revenue in 2024.[21]
  • $14.3 million was Neuronetics’ NeuroStar Advanced Therapy System revenue in 2025, compared with $15.3 million in 2024.[21]
  • $65.4 million was Ceribell’s revenue in 2024, up 45% from $45.2 million in 2023.[21]
  • $17.73 billion was the estimated global neurotechnology-market value in 2025 in Fortune Business Insights’ forecast series.[20]
  • $149.2 million was Neuronetics’ total revenue in 2025, up 99% from $74.9 million in 2024 following the Greenbrook acquisition.[21]

Differentiation in the neurotech industry

  • $65.4 million of Ceribell’s 2024 revenue came from a business combining disposable wearables with hospital software and monitoring subscriptions.[21]
  • 88% was Ceribell’s gross margin in 2025, supported by its wearable, recorder, portal and subscription-based brain-monitoring model.[21]
  • 2 recurring revenue sources supported Ceribell’s 2025 business model: single-patient wearables and monthly hospital subscriptions for Clarity, recorders and its portal.[21]
  • 87% was Ceribell’s gross margin in 2024, compared with 88% in 2025.[21]

Mergers and acquisitions in the neurotech industry

  • 100% of Greenbrook TMS’s outstanding common shares were to be acquired by Neuronetics under the August 2024 arrangement agreement.[21]
  • 0.01149 Neuronetics shares were specified as the expected exchange ratio for each Greenbrook common share in the 2024 all-stock transaction.[21]
  • 57% of the combined company was expected to be owned by Neuronetics shareholders after the Greenbrook transaction, with Greenbrook shareholders owning 43%.[21]
  • $82.5 million of Neuronetics’ 2025 U.S. clinic revenue was added through the Greenbrook acquisition.[21]

Strategic partnerships in the neurotech industry

  • June 1, 2019 marked the effective date of Japanese reimbursement coverage for Neuronetics’ NeuroStar Advanced Therapy System.[21]
  • 1 exclusive distribution agreement gave Teijin rights to distribute Neuronetics’ NeuroStar system and treatment sessions in Japan from 2017 onward.[21]

07 Statistics

People & Workforce

Workforce tracking highlights organization capacity for implementation work, with 334 live neurotechnology and brain-computer-interface roles across 33 companies on November 4, 2026.

Hiring in the neurotech industry

  • 56 listed neurotechnology and BCI roles were in device engineering and manufacturing on November 4, 2026.[22]
  • 21 listed neurotechnology and BCI roles were in research science on November 4, 2026.[22]
  • Neuralink was the largest listed hiring company with 66 neurotechnology and medtech roles on November 4, 2026.[22]
  • 334 live neurotechnology and brain-computer-interface roles were listed across 33 companies on November 4, 2026.[22]
  • 17 listed neurotechnology and BCI roles were in data and artificial intelligence on November 4, 2026.[22]

Remote Work in the medical devices sector (sector benchmark)

  • Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[23]
  • Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[23]
  • Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[23]
  • About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[23]

Hybrid Work in the medical devices sector (sector benchmark)

  • Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[23]
  • Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[23]
  • Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[23]
  • Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[23]

Employee Engagement in the medical devices sector (sector benchmark)

  • In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[24]
  • In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[24]
  • In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[24]
  • Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[24]

Change Management in the medical devices sector (sector benchmark)

  • Only 2% of surveyed medical device manufacturers rated their ability to estimate product-change costs as excellent, while 10% rated it poor.[25]
  • Among post-market medical device companies surveyed in 2023, 23% cited lack of management buy-in as a challenge to improving quality management processes.[15]
  • Among pre-market medical device companies surveyed in 2023, 25% cited resistance to change efforts as a quality-management challenge.[15]
  • Among post-market medical device companies surveyed in 2023, 37% cited resistance to change efforts as a challenge to improving quality management processes.[15]
  • Among pre-market medical device companies surveyed in 2023, 18% cited lack of management buy-in as a challenge to improving quality management processes.[15]

08 Statistics

Customer & Sales

Customer behavior shifts toward digitally influenced decisions; 98% of consumers in a 2026 U.S.-UK survey made repeat purchases from brands recommended by artificial intelligence.

Customer experience in the neurotech industry

  • 77% of U.S. adults favored brain-chip implants to increase movement for paralyzed people, according to a national public-perception survey.[26]
  • 188,662 global patients had been treated with NeuroStar therapy through September 30, 2024, after more than 6.9 million treatment sessions.[27]
  • 39% of surveyed U.S. consumers said they would use a non-invasive brain-sensing device for sleep, focus or mood.[28]
  • 25% of U.S. adults favored brain implants that would let users search the internet through thoughts without typing.[26]

Customer retention in the neurotech industry

  • 98% of consumers in a 2026 U.S.-UK survey made repeat purchases from brands recommended by artificial intelligence; the study included AI-referred digital customers relevant to neurotechnology marketing.[29]
  • 81% of AI-referred consumers said they would not return to a brand after encountering an issue, according to 2026 U.S.-UK customer research.[29]
  • More than 100 million minutes had been logged by InteraXon Muse users worldwide by 2021.[30]
  • 500,000 users worldwide had adopted InteraXon’s Muse neurotechnology platform, according to company information cited by RBC Thought Leadership.[30]

Customer acquisition in the neurotech industry

  • Ceribell’s sales and marketing expense was $49.055 million in 2024, up 26% from $38.922 million in 2023.[31]
  • Ceribell generated $65.444 million in revenue in 2024, up 45% from $45.225 million in 2023 as adoption expanded among new customers.[31]
  • Ceribell reported more than 500 active hospital accounts as of December 31, 2024.[21]

Customer loyalty in the neurotech industry

  • 52% of researchers surveyed by the International Neuroethics Society said some members of the public may distrust adaptive deep-brain-stimulation technologies.[32]
  • 31% of consumers in a 2026 U.S.-UK survey said they would skip a brand flagged by artificial intelligence as having problems.[29]
  • 56% of consumers in a 2026 U.S.-UK survey said they had left a brand that ignored their feedback, a customer-retention risk for neurotechnology brands.[29]
  • 46.5% of German survey respondents expressed trust in researchers to develop brain-computer interfaces responsibly.[33]

Lead generation in the neurotech industry

  • Ceribell’s 2024 product revenue reached $50.079 million, compared with $34.568 million in 2023, reflecting growth in customer adoption and utilization.[31]
  • Ceribell’s 2024 subscription revenue was $15.365 million, up 44% from $10.657 million in 2023.[31]
  • More than 500 active hospital accounts represented Ceribell’s installed commercial account base at December 31, 2024.[21]

09 Statistics

Marketing & Brand

Brand spend remains constrained by channel effectiveness; 1.07% was the average engagement rate for health-industry influencer posts globally in 2023.

Marketing in the neurotech industry

  • Ceribell spent $49.055 million on sales and marketing in 2024, equal to approximately 75% of its $65.444 million total revenue.[31]
  • Customer education was identified by Ceribell as a driver of increased awareness, adoption and headband utilization in 2024.[34]

Digital marketing in the neurotech industry

  • 52% of digital leaders surveyed in 2026 prioritized artificial intelligence for automating customer support.[29]
  • 46% of consumers surveyed in 2026 wanted brands to prioritize artificial intelligence for search support, a digital-discovery use case relevant to neurotechnology products.[29]
  • 52% of digital leaders surveyed in 2026 reported having no process for acting on customer feedback.[29]
  • 45% of digital brands surveyed in 2026 had increased investment in customer-feedback channels, including digital feedback relevant to neurotechnology products.[29]

Branding in the neurotech industry

  • Mood-symptom applications received the lowest average personal-use likelihood rating, 2.56 out of 5, in a 2025 U.S. neurotechnology perception study.[35]
  • 77% of U.S. adults favored the proposed therapeutic use of brain implants to restore movement, indicating stronger public acceptance for medical than enhancement branding.[26]
  • Motor-symptom applications received the highest average personal-use likelihood rating, 3.37 out of 5, in a 2025 U.S. neurotechnology perception study.[35]
  • 25% of U.S. adults favored brain implants for thought-based internet searches, indicating weaker acceptance of enhancement-oriented neurotechnology positioning.[26]
  • DBS was rated the most invasive and risky of four surveyed neurotechnologies in a 1,052-person U.S. public-perception study.[35]

Influencer Marketing in the medical devices sector (sector benchmark)

  • 8% of healthcare and pharmaceutical marketers had dedicated but shrinking budgets for creator or influencer marketing in 2026.[36]
  • 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[36]
  • 1.07% was the average engagement rate for health-industry influencer posts globally in 2023, across the platforms measured by Sprout Social.[37]
  • 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[36]
  • 8.57 million influencer posts about the health industry were published globally in 2023, across the platforms measured by Sprout Social.[37]

10 Statistics

Operations & Execution

Operational performance includes manufacturing scale and adverse-event reporting; 88.8% of documented adverse events were attributed to two surgical-navigation devices covering 2017–2025.

Process optimization in the neurotech industry

  • 25% was Axonics’ year-over-year revenue growth in the third quarter of 2024, when net revenue reached $116.2 million in the United States and internationally.[21]
  • 22% was NeuroPace’s revenue growth in 2024, reaching $79.9 million as increased RNS System and DIXI Medical product volumes improved operating scale.[21]
  • 73.9% was NeuroPace’s gross margin in 2024, up from 73.6% in 2023, primarily because higher RNS System production lowered fixed costs per unit in the United States.[21]
  • 99% was Neuronetics’ reported revenue growth in 2025, reaching $149.2 million after the Greenbrook Treatment Centers acquisition expanded its clinic-service operations in the United States.[21]
  • 27% was electroCore’s net-sales growth in 2025, reaching $32.0 million from $25.2 million in 2024 across the United States, United Kingdom and other markets.[21]

Operational efficiency in the neurotech industry

  • 48.5% was Neuronetics’ gross margin in 2025, compared with 72.3% in 2024 after the company added lower-margin clinic-service revenue in the United States.[21]
  • 75.8% was Axonics’ 2024 adjusted service gross margin, up from 73.6% in 2023 because software revenue represented a larger share of service revenue.[21]
  • 41 NeuroStar systems were shipped by Neuronetics in the second quarter of 2025, while U.S. system revenue totaled $3.5 million.[21]
  • 73.9% was NeuroPace’s gross margin in 2024, reflecting lower fixed costs per unit from increased RNS System production in the United States.[21]
  • 13% was Neuronetics’ pro-forma increase in U.S. treatment-session revenue in the second quarter of 2025, reaching a record quarterly performance after excluding Greenbrook revenue effects.[21]

Quality management in the neurotech industry

  • 88.8% of documented adverse events were attributed to two surgical-navigation devices in the United States neurological-device recall analysis covering 2017–2025.[38]
  • 5% of the 20 software-associated neurological-device recalls in the United States involved stereotactic devices during 2017–2025.[38]
  • 5.9% of 16,333 adverse-event notifications linked to software-associated neurological devices involved injury during 2017–2025 in the United States.[38]
  • 25% of the 20 software-associated neurological-device recalls in the United States involved neurophysiological-monitoring devices during 2017–2025.[38]
  • 15% of the 20 software-associated neurological-device recalls in the United States involved surgical-planning devices during 2017–2025.[38]

Supply chain in the neurotech industry

  • $1.631 million was electroCore’s inventory balance at December 31, 2025, compared with $1.676 million at December 31, 2024.[21]
  • 2 manufacturing partners were planned by Neuronetics for console production, reflecting its stated intention to add a second partner to strengthen the global supply chain in 2025.[21]
  • 3 tiers of suppliers were monitored by Axonics in 2024 to identify and mitigate material shortages and supply disruptions.[21]
  • $4.327 million was Neuronetics’ inventory balance at December 31, 2025, compared with $4.248 million at December 31, 2024.[21]
  • 95% of U.S. payor-covered lives were represented by more than 104 major private insurers and federal healthcare programs covering NeuroStar therapy in 2025.[21]

Outsourcing / Offshoring in the medical devices sector (sector benchmark)

  • 11.4% was the year-over-year growth rate of the global medtech outsourcing market in 2023.[39]
  • $26.3 billion was the U.S. medtech CDMO market in 2023, after 12.9% growth from 2022.[39]
  • $18.5 billion was the European medtech CDMO market in 2023.[39]
  • $81.5 billion was the global medtech outsourcing market in 2023, covering contract development and manufacturing organizations (CDMOs).[39]
  • More than half of 59 global medtech CDMO transactions in 2023 had cross-border characteristics.[39]

11 Statistics

Finance & Pricing

Pricing varies by reimbursement pathway: durable-medical-equipment reimbursement was cited at approximately $5,000 for the Noctrix device.

Pricing strategy in the neurotech industry

  • $5,000–$50,000 was the annual revenue range per organization projected for Neurotech Solutions’ assistive-communication business in 2026.[40]
  • $4,300 was the reported U.S. HCPCS-funded price per NeuroNode device in Neurotech Solutions’ 2026 investor presentation.[40]
  • 10% of Neuronetics’ U.S. revenue in 2025 came from NeuroStar Advanced Therapy Systems.[21]
  • $30,000–$100,000 was the annual revenue range per organization projected for Neurotech Solutions’ Neurotech Solutions platform in 2026.[40]
  • Approximately $3,000 was the wholesale tablet price reported by Neurotech Solutions for 2026.[40]

Cost reduction in the neurotech industry

  • $4 million was NeuroPace’s approximate 2026 stock-based-compensation adjustment for general and administrative expense in its non-GAAP guidance.[21]
  • $10 million was the approximate gap between NeuroPace’s 2026 GAAP operating-expense guidance midpoint and its non-GAAP midpoint after excluding stock-based compensation.[21]
  • $3 million was NeuroPace’s approximate 2026 stock-based-compensation adjustment for sales and marketing expense in its non-GAAP guidance.[21]
  • 20% was NeuroPace’s year-over-year increase in cost of goods sold in 2024, below its 22% revenue growth as production volume increased.[21]
  • $3 million was NeuroPace’s approximate 2026 stock-based-compensation adjustment for research and development expense in its non-GAAP guidance.[21]

Profitability in the neurotech industry

  • $39.1 million was Neuronetics’ net loss in 2025, compared with a $43.7 million net loss in 2024.[21]
  • $27.8 million was electroCore’s gross profit in 2025 on net sales of $32.0 million.[21]
  • $13.2 million was electroCore’s operating loss in 2025, compared with a $12.2 million operating loss in 2024.[21]
  • $3.2 million was Neurotech Solutions’ reported FY2025 EBITDA, according to its May 2026 investor presentation.[40]
  • $72.3 million was Neuronetics’ gross profit in 2025, compared with $54.2 million in 2024.[21]

Financial planning in the neurotech industry

  • 81%–82% was NeuroPace’s 2026 GAAP gross-margin guidance.[21]
  • $90–$92 million was NeuroPace’s 2026 non-GAAP operating-expense guidance after excluding approximately $10 million of stock-based compensation.[21]
  • 49%–50% was Neuronetics’ 2026 gross-margin guidance as of the third quarter of 2026.[27]
  • $160–$164 million was Neuronetics’ unchanged 2026 revenue guidance as of the third quarter of 2026.[27]
  • A$5.4 million was Neurotech Solutions’ capital raised in FY2025, according to its May 2026 investor presentation.[40]

12 Statistics

Product & Service

Device durability and clinical timelines are tracked with numeric endpoints, including 73% ten-year initial-device survival for deep-brain-stimulation systems in a 1994–2015 cohort.

Product development in the neurotech industry

  • $6.584 million was Neuronetics’ research-and-development expense in 2025, including product development, clinical development, regulatory and quality-assurance activities.[21]
  • $650 million was raised by Neuralink in its Series E financing announced in June 2025 to expand patient access and develop brain-interface technology.[41]
  • 30 days is the maximum intended temporary implantation duration for Precision Neuroscience’s Layer 7-T cortical interface cleared by the U.S. FDA.[42]
  • 10 patients were planned for Mount Sinai’s COMMAND trial of Synchron’s Stentrode brain-computer interface, according to the institution’s 2025–2026 program materials.[43]
  • 2 participants were planned for Paradromics’ Connect-One early-feasibility study of its implantable Connexus brain-computer interface in the United States in 2026.[44]

Product lifecycle in the neurotech industry

  • 99.4% of Medtronic Model 304 vagus-nerve-stimulation leads remained implanted and performing as intended after one year in a long-term study.[45]
  • 90% was the five-year initial-device survival rate for vagus-nerve-stimulation systems in a 1994–2015 neuromodulation cohort.[38]
  • 87% was the five-year initial-device survival rate for deep-brain-stimulation systems in a 1994–2015 neuromodulation cohort.[38]
  • 73% was the ten-year initial-device survival rate for deep-brain-stimulation systems in the same 1994–2015 cohort.[38]
  • 2.4% was the three-year replacement rate for rechargeable implantable pulse generators in a 2010–2021 U.S. deep-brain-stimulation review.[18]

After-sales in the neurotech industry

  • 161 NeuroStar systems were shipped by Neuronetics in 2025, according to company-reported investor materials.[21]
  • 248 high-impedance events were recorded in Medtronic’s deep-brain-stimulation registry through October 31, 2023, the largest listed product-performance category.[19]
  • 3.9 product-performance events occurred per 100 patient-years in Medtronic’s deep-brain-stimulation registry through October 31, 2023.[19]
  • $86.977 million was Neuronetics’ clinic-service revenue in 2025, covering services associated with its NeuroStar advanced-therapy business.[21]
  • $6.353 million was Neuronetics’ direct medical-device-segment research-and-development expense in 2025.[21]

Value proposition in the neurotech industry

  • 120,000 or more patients had been implanted with VNS Therapy by 2020, according to LivaNova’s product timeline.[46]
  • 65.7% of first-implanted VNS patients were responders at 12 months in interim CORE-VNS data.[47]
  • 4,012 deep-brain-stimulation patients were enrolled across 66 centers in Medtronic’s registry through October 31, 2024.[19]
  • 10.99% was the average reduction in antiseizure-medication load among first-implanted VNS patients in interim CORE-VNS data.[47]
  • 20.56% of patients in Medtronic’s 2024 deep-brain-stimulation registry were implanted for essential tremor.[19]

13 Statistics

Sustainability & Ethics

Ethics and operations remain coupled in surveys and reporting; 100% of MicroPort NeuroTech’s non-hazardous waste was recycled in 2022.

Sustainability in the neurotech industry

  • 11,149 MWh of green electricity was purchased by MicroPort in 2024.[48]
  • 14% was the approximate annual growth rate of the UK neurotechnology sector as of June 2026.[49]
  • £120 million was the turnover of the UK neurotechnology sector as of June 2026.[49]
  • More than 50 dedicated neurotechnology companies operated in the UK as of June 2026.[49]
  • 40.27 hours was MicroPort NeuroTech’s average employee training time per person in 2023.[50]

ESG in the neurotech industry

  • 37.00 hours was the average training time for female MicroPort NeuroTech employees in 2023.[50]
  • 50% of Neurotech International’s senior executives were female as of June 30, 2023.[51]
  • 89.84% of trained MicroPort NeuroTech employees were classified as other employees in 2023.[50]
  • 45.90 hours was the average training time for male MicroPort NeuroTech employees in 2023.[50]
  • 36.78% of trained MicroPort NeuroTech employees were male in 2023.[50]

Ethics in the neurotech industry

  • 37% of participants judged neurotechnology-based cognitive enhancement morally unacceptable.[52]
  • 66 neural-device industry professionals participated in a comparative neuroethics survey published in 2022.[38]
  • 38% of participants were unsure whether neurotechnology-based cognitive enhancement was morally acceptable.[52]
  • 64% of neuroscience investigators collected neural data in a survey of human-research data-sharing practices.[52]
  • 44% of neuroscience investigators used technologies capable of recording data without active participant participation.[52]

Circular economy in the neurotech industry

  • 50,950 kgCO2e was PD Neurotechnology’s reported total emissions in its first carbon footprint assessment.[53]
  • 100% of MicroPort NeuroTech’s 52.84 tonnes of non-hazardous waste was recycled in 2022.[50]
  • PD Neurotechnology planned to use 100% recyclable packaging for all company products in its carbon-reduction initiatives.[53]
  • 100% of MicroPort NeuroTech’s 20.07 tonnes of hazardous waste was disposed of in 2022.[50]

Carbon footprint in the neurotech industry

  • 50,950 kgCO2e was PD Neurotechnology’s total emissions in its first carbon-footprint assessment.[53]
  • 89.32 tonnes CO2e was MicroPort NeuroTech’s Scope 1 emissions in 2023.[50]
  • 2.50 tonnes CO2e per million RMB of revenue was MicroPort NeuroTech’s greenhouse-gas intensity in 2023.[50]
  • 42.44 tonnes CO2e per million U.S. dollars was MicroPort’s 2024 greenhouse-gas emissions intensity.[48]
  • 1,665.12 tonnes CO2e was MicroPort NeuroTech’s total greenhouse-gas emissions in 2023.[50]

15 Statistics

Globalization & Expansion

International revenue profiles vary: Neuronetics reported $2.012 million international revenue in 2023 (and $2.402 million in 2024).

Globalization in the neurotech industry

  • $2.578 billion was Stryker’s international MedSurg and Neurotechnology revenue in 2024, compared with $9.175 billion in U.S. revenue.[21]
  • $2.402 million in international revenue represented 3% of Neuronetics’ total revenue in 2024, compared with $2.012 million in 2023.[21]
  • $2.877 billion was Stryker’s international MedSurg and Neurotechnology revenue in 2025, compared with $10.815 billion in U.S. revenue.[21]
  • $3.101 billion was Medtronic’s international Neuroscience revenue in fiscal 2024, compared with $6.305 billion in U.S. Neuroscience revenue.[21]
  • $3.109 million in international revenue represented 2% of Neuronetics’ total revenue in 2025, covering NeuroStar systems, treatment sessions and other products worldwide.[21]

Supplier management in the neurotech industry

  • 100% of Ceribell’s 2024 revenue was generated in the United States, indicating no reported international customer revenue in that year.[21]
  • $20,000 was Ceribell’s annual license-maintenance fee to Stanford University in 2025, creditable against a mid-single-digit royalty on licensed-product net sales.[21]
  • $1.0 million was the total value of Vivani Medical’s Neurostimulation Division assets at December 31, 2024; the division included Cortigent and a Swiss subsidiary.[21]

Stakeholder management in the neurotech industry

  • $2 billion was Ceribell’s estimated annual U.S. addressable-market opportunity for acute-care EEG monitoring in 2025.[21]
  • 3 million U.S. acute-care patients were identified by Ceribell as potentially needing EEG monitoring annually because of seizure risk.[21]
  • 327 employees worked at Ceribell in 2025 as the company expanded its acute-care brain-monitoring business.[21]

Distribution channels in the neurotech industry

  • 185 NeuroStar systems were sold in the United States by Neuronetics in 2024 through its direct sales model.[21]
  • 159 NeuroStar systems were sold in the United States by Neuronetics in 2025 through its direct sales model.[21]
  • 3% of Neuronetics’ 2024 sales were international and were marketed through independent distributors in selected markets outside the United States.[21]
  • 98% of Neuronetics’ 2025 sales were generated through its direct U.S. sales force, while non-U.S. sales used local third-party distributors.[21]

Key questions about the Neurotech Industry

What is the current size of the global neurotechnology market?
Fortune Business Insights estimated the global neurotechnology market at $17.73 billion in 2025 and $19.19 billion in 2026.
How fast is the neurotechnology market expected to grow?
The market is forecast to reach $32.93 billion by 2034, implying a 7.0% CAGR from 2026 to 2034.
Which companies lead the neurotech industry?
Boston Scientific leads Gitnux's 2026 neurotech ranking with an Overall score of 9.5, with its Neuromodulation business generating $1.199 billion in 2025 sales. Medtronic is the runner-up at 9.1, driven by Neuroscience Portfolio revenue of $10.287 billion in FY26.
What technology shifts are showing up in practice?
Growth is being driven by adaptive and closed-loop neuromodulation and improved neurodiagnostics, while regulatory pathways diversify by risk.
How is the market structured across offerings and customers?
It is segmented by product into neuroprosthetics, neuromodulation, neurorehabilitation and other technologies, and by end user into hospitals, specialty clinics, homecare settings and other facilities.
Where does regulation currently create gating factors for adoption?
Clinical evidence remains the adoption bottleneck, including FDA Flow FL-100 moderate uncertainty about benefit because of unblinding and the lack of a prespecified clinically significant score change.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, February 13). Neurotech Industry Statistics. Gitnux. https://gitnux.org/neurotech-industry-statistics
MLA
Samuel Norberg. "Neurotech Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neurotech-industry-statistics.
Chicago
Samuel Norberg. 2026. "Neurotech Industry Statistics." Gitnux. https://gitnux.org/neurotech-industry-statistics.

Sources & references

74 sources cited across this report

  1. bcg.com
  2. nsf.org
  3. mastercontrol.com
  4. monitor-industrial-ecosystems.ec.europa.eu
  5. veeva.com
  6. pages.awscloud.com
  7. modeln.com
  8. www-statista-com.libproxy.pcc.edu
  9. ashb.com
  10. eseye.com
  11. ico.org.uk
  12. neurotechnology.com
  13. assets.iec.ch
  14. det.dco.org
  15. blog.greenlight.guru
  16. distillersr.com
  17. sana-suisse-med.ch
  18. sciencedirect.com
  19. medtronic.com
  20. fortunebusinessinsights.com
  21. sec.gov
  22. alion.io
  23. mddionline.com
  24. cultureamp.com
  25. resources.sw.siemens.com
  26. ncses.nsf.gov
  27. ir.neuronetics.com
  28. a16z.com
  29. quantummetric.com
  30. rbc.com
  31. investors.ceribell.com
  32. neuroethicssociety.org
  33. link.springer.com
  34. financialfilings.com
  35. doi.org
  36. brand-news.it
  37. media.sproutsocial.com
  38. pubmed.ncbi.nlm.nih.gov
  39. alirahealth.com
  40. announcements.asx.com.au
  41. neuralink.com
  42. accessdata.fda.gov
  43. icahn.mssm.edu
  44. clinicaltrials.gov
  45. neuroregulation.org
  46. livanova.com
  47. index.mirasmart.com
  48. microport.com
  49. nesta.org.uk
  50. hkexnews.hk
  51. responsibilityreports.com
  52. pmc.ncbi.nlm.nih.gov
  53. pdneurotechnology.com
  54. oecd.org
  55. cognition.us
  56. greenlight.guru
  57. runsafesecurity.com
  58. deloitte.com
  59. mdic.org
  60. dennemeyer.com
  61. 2bridge.partners
  62. mordorintelligence.com
  63. neurotechreports.com
  64. neurovision.com
  65. news.medtronic.com
  66. news.bostonscientific.com
  67. ceribell.com
  68. blackrockneurotech.com
  69. investor.livanova.com
  70. precisionneuro.io
  71. assets.cochlear.com
  72. paradromics.com
  73. market-reports.com
  74. ir.clearpointneuro.com